1. Rapamycin Extends Life Span in Apc Colon Cancer FAP Model
- Author
-
Manish Parihar, Randy Strong, Martin A. Javors, Zelton D Sharp, Paul Hasty, Gene Hubbard, and Sherry G. Dodds
- Subjects
Male ,Heterozygote ,Time Factors ,Carcinogenesis ,Colon ,Colorectal cancer ,Adenomatous Polyposis Coli Protein ,Crypt ,Mice, Transgenic ,mTORC1 ,Mechanistic Target of Rapamycin Complex 1 ,Article ,Familial adenomatous polyposis ,Mice ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Animals ,Humans ,Medicine ,Intestinal Mucosa ,Sirolimus ,business.industry ,Azoxymethane ,Gastroenterology ,medicine.disease ,Survival Analysis ,digestive system diseases ,Colon polyps ,Disease Models, Animal ,Oncology ,chemistry ,030220 oncology & carcinogenesis ,Colonic Neoplasms ,Cancer research ,Immunohistochemistry ,Phosphorylation ,Female ,030211 gastroenterology & hepatology ,business - Abstract
MICRO: Rapamycin extends life and health span in wild type mice suggesting prevention of cancer. We show rapamycin extends survival in colon cancer prone mice and that crypt cells are primary targets of mTOR inhibition that mediate tumor prevention or delay. STRUCTURED: We previously showed that lifelong rapamycin treatment of short lived Apc(Min/+) mice, a model for familial adenomatous polyposis (FAP), resulted in a normal lifespan. Apc(Min/+) mice develop colon polyps with a low frequency but can be converted to a colon cancer model by dextran sodium sulfate (DSS) treatments (Apc(Min/+)-DSS model). We asked, what effect would pretreatment of Apc(Min/+) mice with chronic rapamycin prior to DSS exposure have on survival and colonic neoplasia? Forty-two ppm eRapa diet exacerbated the temporary weight loss associated with DSS treatment in both sexes. However, our survival studies showed that chronic rapamycin treatment significantly extended lifespan of Apc(Min/+)-DSS mice (both sexes) by reductions in colon neoplasia and prevention of anemia. Rapamycin also had prophylactic effects on colon neoplasia induced by azoxymethane (AOM) and DSS in C57BL/6 males and females. Immunoblot assays showed the expected inhibition of mTORC1 and effectors (S6K→rpS6 and S6K→eEF2K→eEF2) in colon by lifelong rapamycin treatments. To address the question of cell types affected by chronic enteric rapamycin treatment, immunohistochemistry analyses demonstrated that crypt cells had a prominent reduction in rpS6 phosphorylation and increase in eEF2 phosphorylation relative controls. These data indicate that enteric rapamycin prevents or delays colon neoplasia in Apc(Min/+)+DSS mice through inhibition of mTORC1 in the crypt cells.
- Published
- 2021
- Full Text
- View/download PDF